<DOC>
	<DOCNO>NCT00568672</DOCNO>
	<brief_summary>Evaluation olanzapine versus placebo continuation therapy subject major depression response additional olanzapine antidepressant .</brief_summary>
	<brief_title>Optimal Duration Olanzapine Add-on Therapy Major Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>inform consent age 18 80 diagnosis major depression accord dsmiv , unipolar course HamiltonDepressionRatingScale ( 17 item score ) &gt; 18 prior inclusion response towards therapy antidepressant olanzapine define &gt; 50 % reduction HAMDD score negative pregancy test highly effective contraceptive method woman participation trial accord German Drug Laq normal liver function pregnancy , lactation depressive episode secondary somatic disease substance dependency contraindication olanzapine treatment interact substance ( CYP1A2 inhibitor inductor ) comorbidity accord DSMIV , axis I denail consent hospital treatment legal order hepatic insufficiency severe neurological medical disease adipositas permagna HIVinfection active viral hapatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>add-on therapy</keyword>
	<keyword>antidepressant</keyword>
	<keyword>atypical antipsychotic</keyword>
</DOC>